Health Care & Life Sciences » Pharmaceuticals | Corcept Therapeutics Inc.

Corcept Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
10,357.00
26,551.00
50,286.00
81,321.00
159,201.00
251,247
Cost of Goods Sold (COGS) incl. D&A
143.00
882.00
1,361.00
2,058.00
3,554.00
5,215
Gross Income
10,214.00
25,669.00
48,925.00
79,263.00
155,647.00
246,032
SG&A Expense
51,710.00
53,288.00
52,368.00
69,084.00
102,792.00
156,536
EBIT
41,496.00
27,619.00
-
10,179.00
52,855.00
89,496
Non Operating Income/Expense
115.00
64.00
117.00
110.00
407.00
2,657
Interest Expense
4,400.00
3,700.00
2,848.00
1,929.00
456.00
-
Pretax Income
46,011.00
31,383.00
6,408.00
8,140.00
52,806.00
92,153
Income Tax
-
-
-
-
76,316.00
16,743
Consolidated Net Income
46,011.00
31,383.00
6,408.00
8,140.00
129,122.00
75,410
Net Income
46,011.00
31,383.00
6,408.00
8,140.00
129,122.00
75,410
Net Income After Extraordinaries
46,011.00
31,383.00
6,408.00
8,140.00
129,122.00
75,410
Net Income Available to Common
46,011.00
31,383.00
6,408.00
8,140.00
129,122.00
75,410
EPS (Basic)
0.46
0.31
0.06
0.07
1.04
0.60
Basic Shares Outstanding
99,819.00
100,978.00
106,883.00
110,566.00
113,527.00
115,343
EPS (Diluted)
0.46
0.31
0.06
0.07
1.04
0.60
Diluted Shares Outstanding
99,819.00
100,978.00
106,883.00
110,566.00
124,515.00
126,688
EBITDA
41,422.00
27,478.00
3,288.00
10,266.00
52,961.00
89,732

About Corcept Therapeutics

View Profile
Address
149 Commonwealth Drive
Menlo Park California 94025
United States
Employees -
Website http://www.corcept.com
Updated 07/08/2019
Corcept Therapeutics, Inc. engages in the development of drugs for the treatment of severe psychiatric, neurological, and metabolic disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.